The association of time and medications with changes in bone mineral density in the 2 years after critical illness by Orford, Neil R. et al.
RESEARCH Open Access
The association of time and medications
with changes in bone mineral density in
the 2 years after critical illness
Neil R. Orford1,2,3,8*, Michael Bailey2, Rinaldo Bellomo2, Julie A. Pasco1,3,4,5, Claire Cattigan1,3, Tania Elderkin1,
Sharon L. Brennan-Olsen3,5,6,7, David J. Cooper2 and Mark A. Kotowicz3,5,6
Abstract
Background: Critical illness is associated with increased risk of fragility fracture and loss of bone mineral density
(BMD), although the impact of medication exposures (bone anti-fracture therapy or glucocorticoids) and time
remain unexplored. The objective of this study was to describe the association of time after ICU admission, and
post-ICU administration of bone anti-fracture therapy or glucocorticoids after critical illness, with change in BMD.
Methods: In this prospective observational study, conducted in a tertiary hospital ICU, we studied adult patients
requiring mechanical ventilation for at least 24 hours and measured BMD annually for 2 years after ICU discharge. We
performed mixed linear modelling to describe the association of time, and post-ICU administration of anti-fracture
therapy or glucocorticoids, with annualised change in BMD.
Results: Ninety-two participants with a mean age of 63 (±15) years had at least one BMD assessment after ICU
discharge. In women, a greater loss of spine BMD occurred in the first year after critical illness (year 1: -1.1 ± 2.0% vs
year 2: 3.0 ± 1.7%, p = 0.02), and anti-fracture therapy use was associated with reduced loss of BMD (femur 3.1 ± 2.4%
vs -2.8 ± 1.7%, p = 0.04, spine 5.1 ± 2.5% vs -3.2 ± 1.8%, p = 0.01). In men anti-fracture and glucocorticoid use were
not associated with change in BMD, and a greater decrease in BMD occurred in the second year after critical illness
(year 1: -0.9 ± 2.1% vs year 2: -2.5 ± 2.1%, p = 0.03).
Conclusions: In women a greater loss of spine BMD was observed in the first year after critical illness, and anti-fracture
therapy use was associated with an increase in BMD. In men BMD loss increased in the second year after critical illness.
Anti-fracture therapy may be an effective intervention to prevent bone loss in women after critical illness.
Keywords: Critical illness, Long-term outcomes, Osteoporosis, Fracture, Bone loss, Bone mineral density, Bone
turnover marker
Background
Over the last two decades the focus of research on in-
tensive care outcomes has broadened from survival to
include morbidity and quality of life [1–10]. To date,
interventions aimed at improving recovery after critical
illness have had a functional focus - physical therapy
programs [11, 12], mental health support [13], and
follow-up clinics [14–16] - but met with limited success
[17]. However, there has been little focus on post-
intensive care unit (ICU) bone loss, a potentially treat-
able condition.
In recent years, an association between critical illness
and accelerated bone turnover has been described, in-
cluding an increase in bone turnover markers (BTM)
during critical illness [18], accelerated loss of bone min-
eral density (BMD) in the year following critical illness
[19], and increased fragility fractures in survivors of crit-
ical illness [20]. This association was, as expected, most
pronounced in older women [19, 20]. The annual change
in femur and spine BMD in women that survived critical
illness was -1.96% and -2.85%, compared to -0.65% and
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-0.18% in age-matched community controls [19]. The
risk of fragility fracture for women greater than 60 years
of age was significantly higher following critical illness
than age-matched controls [20].
However the duration of this effect, and the potential
impact of medications that are known to adversely (such
as glucocorticoids [21, 22]) or positively (anti-fracture
therapy) affect BMD and fracture risk, are not fully eluci-
dated, and no long-term prospective studies have de-
scribed the BMD outcome association after critical illness.
The aim of this study was to describe the association
of time, post-ICU administration of bone anti-fracture
therapy and glucocorticoids on change in BMD over a
2-year period in survivors of critical illness.
Methods
Design, ethics and consent
We conducted a prospective observational cohort study
of longitudinal changes in BMD for a 2-year period after
critical illness. Prior to commencement, approval was
obtained from the Barwon Health Human Research Ethics
Committee. Written informed consent was obtained from
surrogate decision-makers and patients for inclusion for
the first year of the study [19]. Subsequent consent was
obtained from patients to extend follow-up to 2 years post
critical illness.
Study population
Adult (age greater than 20 years) patients admitted to a
tertiary, mixed medical, surgical, and cardiac surgical
ICU during the study period, and with duration of
mechanical ventilation greater than 24 hours were eli-
gible for enrolment in the study. Exclusion criteria in-
cluded active malignancy, existing neurological illness
with impaired weight bearing, inability to lie flat, meta-
bolic bone disease, pregnancy, weight greater than 120
kilograms, and considered unlikely to survive by the
treating intensivist. Patients with multiple ICU admis-
sions during the study period were included for the first
ICU admission only.
Data collection
Data collected included demographics, osteoporosis risk
factors [parental history of hip fracture, previous fragility
fracture, body mass index (BMI) less than 20, current
smoking, use of glucocorticoids, rheumatoid arthritis, al-
cohol consumption of three units daily or greater, or sec-
ondary causes of osteoporosis], information relating to
critical illness and ICU interventions, ICU and hospital
length of stay, survival, serum biochemistry, serum bone
formation marker: type 1 N-terminal procollagen
(P1NP), serum bone resorption marker: collagen type 1
cross-linked c-telopeptide (CTX), and BMD. BMD was
measured by dual-energy X-ray absorptiometry (DXA)
(Lunar; GE Healthcare, Madison, WI, USA), at the prox-
imal femur (femoral neck) and lumbar spine. Short-term
precision in vivo was 1.6% for the femoral neck and 0.6%
for the lumbar spine. Details on the measurement of
serum BTMs are provided in Additional file 1. Medication
history included medications taken by participants prior
to critical illness, during critical illness, and during follow-
up periods. Use of anti-fracture therapy was defined as use
of a bisphosphonate, strontium ranelate, teriparatide,
denosumab, or raloxifene, in the previous year. Use of glu-
cocorticoids was defined as greater than 3 months’ use in
the previous year at a dose of prednisolone of 5 mg daily
or more (or equivalent dose of other glucocorticoids).
Data were collected at ICU baseline (demographic data,
clinical information, BTMs), post-ICU discharge (BMD),
1-year post-ICU discharge (BMD, BTMs, clinical informa-
tion), and 2-year post-ICU discharge (BMD, clinical infor-
mation). Details of the study operating procedure are
provided in Additional file 2. BMD was presented as an
absolute value (g/cm2), annualised percentage change
(difference between BMDs divided by initial post-ICU
discharge BMD calculated as an annualised rate), and
categorised as normal (T-score > -1.0), osteopenic (T-
score -2.5 to -1.0), or osteoporotic (T-score < -2.5).
The T-score is the number of standard deviations
above or below the young adult mean, based on
WHO criteria [23] with cutoff values calculated from
the Australian reference ranges [24, 25].
Outcomes
The outcomes of the study were annualised percentage
change compared to baseline BMD (lumbar spine and
dual femoral neck) for each of the 2 years after ICU dis-
charge. The effect of the post-ICU variables including
year post-ICU discharge, anti-fracture therapy use, and
glucocorticoid use, on annual percentage change in
BMD were also assessed.
Statistical analysis
All data were initially assessed for normality. Group com-
parisons were performed using chi-square tests for equal
proportion, Student t tests for normally distributed data
and Wilcoxon rank sum tests otherwise, with results
reported as number (%), mean (standard deviation) or me-
dian (interquartile range) respectively. Mixed linear mod-
elling was used to explore the nature of the relationship
between anti-fracture therapy use, glucocorticoid use, and
the mean annualised change in bone mineral density using
all available data. Given the known differences in BMD
between men and women, all results have been stratified
by sex. To account for potential survival bias due to par-
ticipant drop-out, additional sensitivity analysis was con-
ducted considering only patients that completed all three
BMD measurements over the 2-year study period. Finally,
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to further establish the duration and magnitude of change
in BMD after critical illness in the absence of known mod-
ifiers, a final subgroup of completers excluding those with
post-ICU glucocorticoid or anti-fracture therapy use was
considered. All modelling results are reported as least
square means ± standard errors and a two-sided p value of
0.05 was used to indicate statistical significance. Statistical
analysis was performed using SAS version 9.4 (SAS Insti-
tute Inc., Cary, NC, USA), with figures produced using
Graphpad Prism 7.0 © (GraphPad Software, San Diego,
CA, USA).
Results
Patient enrolment
A total of 92 of 138 patients enrolled in the study during
their ICU stay underwent initial BMD assessment
following ICU discharge and were eligible for this study.
Of the 92 subjects, 66 had two BMD assessments, and
48 had all three BMD assessments over the 2-year study
period (Fig. 1).
Baseline characteristics
Baseline characteristics are presented in Table 1 strati-
fied by BMD assessment status. Overall 40 (44%) of par-
ticipants had at least one osteoporosis risk factor, 29
(32%) received glucocorticoids during critical illness,
median ICU length of stay was 6 days [IQR 4,9], and
hospital length of stay was 16 days [IQR 11,30]. Mortal-
ity at 1 year was 9%, and at 2 years was 11%. The 48
participants that completed all BMD assessments and
were included in the sensitivity analysis were compared
to the 44 participants that withdrew or died prior to
completion of all BMD assessments. The groups had
similar characteristics, except for an increased preva-
lence of osteoporosis risk factors (57% vs 31%, p = 0.02)
in the group that withdrew or died prior to completion
of all assessments.
Change in BMD and association with time, anti-fracture
therapy and glucocorticoids
Over the 2-year post-ICU period 92 participants under-
went a total of 114 measurements of annual change in
BMD (post-ICU year 1 n = 66, post-ICU year 2 n = 48)
(Table 2). Over the 2-year period ten participants were
prescribed anti-fracture therapies (six women, four men),
including alendronate (five participants), denosumab (two
participants), strontium ranelate (two participants), and
risedronate (one participant). Three (10%) women and
one (3%) man received anti-fracture therapies in year 1
post-ICU, and six (27%) women and four (15%) men re-
ceived anti-fracture therapies in year 2. Glucocorticoids
were received by two (7%) women and one (2%) man in
year 1 post-ICU, and five (23%) women in year 2.
In 44 women with 53 measurements of annual change
in BMD over the 2-year period, a significantly greater
decrease in BMD was observed in post-ICU year 1 com-
pared to year 2 for spine BMD (year 1: -1.1 ± 2.0% vs
year 2: 3.0 ± 1.7%, p = 0.02), but not femur BMD (year 1:
Fig. 1 Summary of eligibility, enrolment, and follow-up of patients undergoing BMD assessment following intensive care. Abbreviations: BMD bone
mineral density, BTM bone turnover markers, ICU intensive care unit
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Table 1 Demographic, clinical characteristics, baseline bone turnover markers, biochemistry, and outcomes by bone mineral density
assessments at 2-year follow-up
Variable All (n = 92) Completed three BMD
assessments (n = 48)
Completed one to two
BMD assessments (n = 44)
p value
Age (yrs) 63.4 (±14.7) 65.8 (±11.4) 60.8 (±17.4) 0.1
BMI 27.1 (±5.1) 27.2 (4.4) 27.1 (5.8) 0.9
Women 44 (47.8) 22 (45.8) 22 (50.0) 0.8
Any osteoporosis risk factor 40 (43.5) 15 (31.3) 25 (56.8) 0.02
Co-morbidity
Renal 7 (7.6) 4 (8.3) 3 (6.8) 1.0
Cardiovascular 40 (43.5) 22 (45.8) 18 (40.9) 0.7
Respiratory 22 (23.9) 8 (16.7) 14 (31.8) 0.1
APACHE III score 74.4 (±29.5) 76.3 (±29.3) 72.4 (±30.0) 0.5
ICU admission category
Medical 54 (58.7) 26 (54.2) 28 (63.6)
Cardiothoracic surgery 16 (17.4) 10 (20.8) 6 (13.6)
General surgery 22 (23.9) 12 (25.0) 10 (22.7)
ICU biochemistry and biomarkers
Albumin (g/L) 23.9 (±5.8) 23.6 (±5.9) 24.1 (±5.7) 0.6
Calcium adj (mmol/L) 1.99 (±0.33) 2.01 (±0.32) 1.96 (±0.33) 0.5
Creatinine (umol/L) 116 [85, 178] 125 [85, 175] 109 [89, 196] 0.7
Vitamin D (nmol/L) 44.2 (±20.2) 43.4 (±20.0) 45.1 (±20.7) 0.7
Phosphate (mmol/L) 0.70 [0.52, 1.00] 0.67 [0.49, 1.04] 0.72 [0.52, 0.96] 0.7
PTH (pmol/L) 9.29 (±7.51) 9.88 (±7.94) 8.65 (±7.05) 0.4
CTX (ng/L) 581 [400, 851] 581 [386, 884] 581 [414, 837] 1.0
P1NP (ug/L) 31.5 [22.0, 60.0] 30.5 [22.0, 46.0] 32.5 [22.5, 87.0] 0.2
Hospital interventions/outcomes
Ventilation duration (hrs) 86.0 [47.4, 146.0] 80.4 [43.9, 118.0] 91.9 [52.3, 215.0] 0.1
Glucocorticoid 29 (31.5) 16 (33.3) 13 (29.5) 0.8
CRRT 15 (16.3) 6 (12.5) 9 (20.5) 0.3
ICU LOS (days) 6 [4, 9] 7 [4, 8] 6 [4, 11] 0.9
Hospital LOS (days) 16 [11, 30] 15 [11, 28] 17 [10, 32] 0.7
Baseline BMD (post-ICU discharge)
ICU admit to BMD (days) 33 [13,58] 36 [14, 63] 33 [12,56]
T-score femur -0.8 (±1.5) -1.0 (±1.4) -0.7 (±1.5) 0.3
Absolute femur (g/cm3) 0.956 (±0.197) 0.941 (±0.183) 0.974 (±0.212) 0.4
T-score AP spine 0.1 [-1.4, 1.0] -0.1 [-1.6, 0.8] 0.1 [-1.3, 1.2] 0.4
Absolute AP spine (g/cm3) 1.207 (±0.242) 1.200 (±0.228) 1.210 (±0.261) 0.7
Mortality
1-year 8 (8.7) 0 (0) 8 (18.2)
2-year 10 (10.9) 0 (0) 10 (22.7)
Data are shown as mean (±standard deviation), median [interquartile range] or number (%). Complete BMD follow-up defined as all three post-ICU measurements
performed during the 2-year period. Incomplete BMD follow-up defined as one or two post-ICU measurements performed. Reference ranges: vitamin D
(<25 nmol/L = deficient, 25–50 nmol/L insufficient, >50 nmol/L sufficient), PTH (range 1.6–6.9 pmol)
Abbreviations: BMD bone mineral density, BMI body mass index, APACHE Acute Physiology and Chronic Health Evaluation, ICU intensive care unit, PTH parathyroid
hormone, CTX collagen type 1 cross-linked c-telopeptide, P1NP type 1 N-terminal procollagen, CRRT continuous renal replacement therapy, LOS length of stay,
AP anterioposterior
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-0.3 ± 1.9% vs year 2: 0.6 ± 1.7%, p = 0.6) (Fig. 2a). The use
of anti-fracture therapy associated with a significant differ-
ence in post-ICU annual change of BMD, with an increase
in BMD in participants who received anti-fracture medi-
cation compared to a decrease in those that did not
(femur 3.1 ± 2.4% vs -2.8 ± 1.7%, p = 0.04, spine 5.1 ± 2.5%
vs -3.2 ± 1.8%, p = 0.01). In women use of glucocorticoids
was not associated with a difference in annual change in
BMD compared to no use (femur -0.2 ± 2.7% vs 0.5 ±
1.6%, p = 0.8, spine 0.5 ± 2.9% vs 1.4 ± 1.6%, p = 0.8).
In 48 men with 61 measurements of annual change in
BMD over the 2-year period, a greater annual decrease
in femur BMD was observed in post-ICU year 2 com-
pared to year 1 (year 1: -0.9 ± 2.1% vs year 2: -2.5 ± 2.1%,
p = 0.03), with no difference in annual change of spine
BMD (year 1: 0.9 ± 4.0% vs year 2: 2.1 ± 4.0%, p = 0.45).
In men no association between anti-fracture therapy use
and annual change in BMD was observed (femur -0.4 ±
2.5% vs -3.0 ± 2.0%, p = 0.1, spine 2.4 ± 4.8% vs 0.7 ±
3.6%, p = 0.6) (Fig. 2b). As only one male participant
received glucocorticoids, analysis was not performed.
The sensitivity analysis for the 48 participants who
completed all three BMD assessments is presented in
Additional files 3 and 4. For women the percentage of
participants with osteoporosis or osteopenia was 59% at
ICU discharge, 68% at year 1, and 59% at year 2. In men
the proportion was 39% at ICU discharge, 50% at year 1,
and 54% at year 2. The results of sensitivity analysis for
this group are presented in Additional file 4, and are
consistent with the primary analysis.
Annual change in BMD in participants not receiving
glucocorticoids or anti-fracture therapy
The annual change in BMD in the first and second years
after ICU discharge in the cohort of participants who
did not receive either glucocorticoids or anti-fracture
therapies are presented by sex in Fig. 3a and b. In
women an annual decrease in femur and spine BMD
was observed for both year 1 and 2, with no significant
change over the 2-year period (femur -2.8 ± 1.3% vs -1.9
± 0.7, p = 0.6, spine -4.8 ± 1.4% vs -1.3 ± 1.8%, p = 0.08).
In men the annual decrease in femur BMD was signifi-
cantly greater in year 2 than year 1 (femur -1.9 ± 0.7% vs
-3.2 ± 0.7%, p = 0.03), with no difference in annual spine
BMD change between year 1 and year 2 (spine 0.0 ±
1.2% vs 0.9 ± 1.5%, p = 0.6).
Discussion
Key findings
We studied the association between time, post-ICU ad-
ministration of bone anti-fracture therapy and glucocor-
ticoids, and annual change in BMD over a 2-year period
after critical illness. In women a significantly greater loss
of spine BMD was observed in the first year after ICU
compared to the second. In women who did not receive
anti-fracture therapy or glucocorticoids, a decrease in
BMD was observed in both years after ICU discharge.
However, post-ICU administration of anti-fracture ther-
apy was associated with an increase in BMD, compared
to a decrease in women who did not. In men, loss of
femur BMD was significantly greater in the second year
after ICU discharge. There was no association between
use of anti-fracture therapy or glucocorticoids and
change in BMD, although only a small number of men
received post-ICU treatment.
Relationship to previous studies
Loss in BMD following critical illness has been reported
in two previous studies. A significant decrease in calca-
neal BMD was observed over 10 days in patients with
Table 2 Bone mineral density assessments performed and results for entire cohort by gender
All (n = 92a) Women (n = 44a) Men (n = 48a)
Variable Baseline 1 year 2 years Baseline 1 year 2 years Baseline 1 year 2 years
BMD studies performed 92 66 48 44 31 22 48 35 26
Anti-fracture therapy in
prior year
- 4 (6.1) 10 (20.8) - 3 (9.7) 6 (27.3) - 1 (2.9) 4 (15.4)
Glucocorticoid in prior year - 3 (4.5) 5 (10.4) - 2 (6.5) 5 (22.7) - 1 (2.9) 0 (0)
BMD measurement
Femur T-score - 0.8 (±1.5) -1.0 (±1.4) - 1.1 (±1.3) - 1.2 (±1.4) - 1.3 (±1.2) - 1.4 (±0.9) - 0.5 (±1.4) - 0.7 (±1.5) - 1.0 (±1.6)
Femur absolute (g/cm3) 0.956
(±0.197)
0.940
(±0.193)
0.923
(±0.178)
0.876
(±0.176)
0.872
(±0.161)
0.871
(±0.126)
1.028
(±0.187)
0.999
(±0.202)
0.964
(±0.203)
AP spine T-score - 0.2 (±1.9) - 0.2 (±1.9) - 0.1 (±1.9) - 0.7 (±1.8) - 0.6 (±1.6) - 0.5 (±1.2) 0.3 (±1.8) 0.2 (±2.0) 0.3 (±2.2)
AP spine absolute (g/cm3) 1.207
(±0.242)
1.205
(±0.241)
1.211
(±0.231)
1.135
(±0.250)
1.142
(±0.223)
1.151
(±0.173)
1.273
(±0.217)
1.260
(±0.246)
1.262
(±0.264)
Data are shown as mean (±standard deviation) or number (%)
Abbreviations: BMD bone mineral density, AP anterioposterior
aAt baseline femur BMD not measured in three participants (one woman, two men). At 1 year femur BMD not measured in two participants (one woman, one
man), at 2 years femur BMD not measured in one participant (one woman)
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acute respiratory distress syndrome [26], although this
result is limited by precision error of portable BMD de-
vices and short time frame [27]. We described a signifi-
cant decrease in spine and femur BMD in the first year
after ICU admission, greater than age- and gender-
matched community controls, in the initial cohort from
this study [19]. In addition a number of studies have de-
scribed abnormal BTMs during and after critical illness,
of a magnitude similar to that described in postmeno-
pausal women’s or metabolic bone disease [19, 28–34].
High bone turnover and bone loss, due to negative re-
modelling balance at the basic multicellular unit, has
been described as an independent risk factor for fracture
[29, 35]. An increased fracture risk in older women after
intensive care compared to matched population controls
has been described [20].
The extension of BMD assessment to 2 years after crit-
ical illness in this study adds important information
about the time course and magnitude of changes in
BMD following critical illness [19, 26]. In women we ob-
served a loss in femur and spine BMD in the first 2 years
after critical illness, with recovery of BMD observed in
women receiving anti-fracture therapy. The reported
change in BTMs after critical illness describes increased
resorption markers during and after ICU [19, 28–34],
followed by increased formation markers and normalisa-
tion of resorption markers by 1 year [19]. The magni-
tude of this decrease was greater than we have
previously observed in community controls [19], sup-
porting the hypothesis that factors associated with crit-
ical illness contribute to an increase in bone loss, and
that administration of anti-fracture therapy is a major
determinant of BMD recovery after critical illness. The
different pattern of BMD loss in men compared to
women following critical illness is also of interest. The
observed decrease in femur BMD is consistent with our
Fig. 2 a RMANOVA assessment of annual BMD change in women. Abbreviations: BMD bone mineral density, RMANOVA repeat measure analysis of
variance, SE standard error. b RMANOVA assessment of annual BMD change in men. Abbreviations: BMD bone mineral density, RMANOVA repeat
measure analysis of variance, SE standard error
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previous study of change in BMD after ICU compared
to community controls [19]. The significantly greater
loss in femur BMD in the second year after ICU dis-
charge, the high proportion of men with osteoporosis
and osteopenia at 2 years post-ICU discharge, and the
low rate of post-ICU anti-fracture treatment, suggest
further investigation of risk factors and consequences of
bone loss in men is warranted.
The current literature regarding the relationship be-
tween anti-fracture therapy use and change in BMD
following critical illness is limited. A small study re-
ported a transient decrease in bone resorption markers
after administration of intravenous ibandronate [36], and
a retrospective propensity-matched cohort study described
an association between pre-ICU bisphosphonate use and
reduced mortality [37]. In addition, serial computed tomog-
raphy (CT) assessment of vertebral BMD revealed bisphos-
phonate users had lower baseline bone density and an
attenuated decrease in BMD during critical illness. This
study is the first to prospectively describe an association be-
tween anti-fracture therapy use and change in BMD over a
prolonged period following critical illness. The observed in-
creased proportion of anti-fracture therapy use in women is
expected, based on lower measured BMDs in the years after
critical illness. The observed positive association between
anti-fracture therapy use and BMD provides support for
future interventional studies in this population.
The observation that use of glucocorticoid, a known
risk factor for osteoporosis, was not associated with an
increase in annual change in BMD was interesting, al-
though limited by small sample size and the risk of type
II error. More prospective data on the relationship be-
tween BMD changes following critical illness and the ef-
fect of known osteoporosis factors, including medications
administered before and after critical illness, are required
to further elucidate these relationships.
Fig. 3 a Annual change in BMD in women not receiving anti-fracture or corticosteroid medications. b Annual change in BMD in men not receiving
anti-fracture or corticosteroid medications. Abbreviations: BMD bone mineral density, ICU intensive care unit, SE standard error
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Study implications
This study implies that critical illness is associated with
prolonged and sustained loss of BMD, with variable ef-
fects on femur and spine in women and men. Although
recovery of BMD occurs overall in women, this may be
associated with the use of anti-fracture therapy in the
post-ICU period. This implies that anti-resorptive ther-
apy may be an effective intervention to prevent bone
loss in women with critical illness as has been shown in
other at-risk patients.
Strengths and limitations
Our study has several strengths. It is the first study to
collect prospective data on bone density using DXA, the
gold standard for BMD assessment, over a 2-year period
after critical illness. This is important because the previ-
ously described changes in bone mineral density that
occur immediately after critical illness may be attenuated
over time. Moreover, understanding of the natural his-
tory of these changes can be used to guide the need and
design of interventional trials. In addition, the collection
of post critical illness medication history allows assess-
ment of factors that are known to modify bone turnover,
over a time frame required to assess this effect.
There are limitations to this study. The loss of a large
proportion of patients prior to the 2-year follow-up due
to death or withdrawal introduces limitations due to
small sample size, including ability to assess the impact
of multiple risk factors on post critical illness change in
BMD, perform subgroup analysis, and introduces the
possibility of type II error. However, the ability to assess
the effect of anti-fracture therapy and glucocorticoids,
although limited by numbers, provides unique and valu-
able information about feasibility and design of an inter-
ventional study. Also, the assessment of glucocorticoid
use following critical illness was defined as use for
greater than 3 months in the previous year, and it is pos-
sible that shorter duration of glucocorticoids during crit-
ical illness or recovery were associated with a change in
BMD that was not captured. However, glucocorticoids
are a known risk factor for loss of BMD, and a much lar-
ger study would be required to assess the effect of gluco-
corticoids administered before, during, and after ICU.
Also, data relating to a number of variables associated
with BMD was not collected, including other medica-
tions that affect bone turnover, nutrition, falls, and frac-
tures. However, given the small sample size, analysis of
the relationship between these factors and BMD would
not have been possible. Finally, anti-fracture medications
were clinician-initiated rather than randomised, introdu-
cing selection bias into the results. However, anti-
fracture therapies are initiated in the highest risk
patients with the lowest BMD, with the effect observed
in this study likely to underestimate that observed in a
mixed population of critically ill patients.
Conclusions
We performed a prospective observational study of changes
in BMD in critically ill, mechanically ventilated subjects,
and observed a high prevalence of osteopenia and osteopor-
osis at 2 years post-ICU discharge. In women participants,
a greater loss of spine BMD was observed in the first year
after critical illness, with anti-fracture therapy use associ-
ated with an increase in BMD compared to a decrease in
BMD in those that did not receive such therapy. In men
BMD loss increased in the second year after critical illness,
and there was no association between use of anti-fracture
therapy or glucocorticoids and change in BMD, although
only a small proportion of men received post-ICU bone-
related medications. These findings suggest anti-fracture
therapy may be an effective intervention to prevent bone
loss in women with critical illness, and prospective trials in-
vestigating this effect are warranted.
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